12:28 uur 10-12-2015

New England Journal of Medicine publiceert baanbrekend onderzoek dat voordelen Pulmonx’ medische instrumenten tegen emfyseem aantoont

REDWOOD CITY, Calif.–(BUSINESS WIRE)– Pulmonx Corporation, leider in interventionele longgeneeskunde, heeft de online publicatie van de resultaten van het onafhankelijke, gerandomiseerde en gecontroleerde STELVIO-onderzoek in het New England Journal of Medicine aangekondigd. Dit onderzoek toonde statistisch en klinisch significante resultaten aan in longfunctie, bewegingscapaciteit en kwaliteit van leven bij patiënten met een ernstig emfyseem dat is opgespoord met Pulmonx’ Chartis® System en behandeld met de Zephyr® Endobronchial Valve (EBV). Het onderzoek vergeleek deze methode met de standaardprocedure.

STELVIO is het eerste gerandomiseerde, gecontroleerde onderzoek naar therapie met de Zephyr EBV en het Chartis System. Dat laatste systeem wijst uit welke patiënten de grootste kans hebben op voordeel uit de behandeling. STELVIO is tevens het eerste prospectieve onderzoek dat aantoont dat Zephyr EBV voordelen heeft voor veel patiënten met een vergevorderd emfyseem, met inbegrip van mensen bij wie het emfyseem in specifieke delen van de longen zit geïsoleerd. Het onderzoek is onafhankelijk van Pulmonx uitgevoerd.

New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Pulmonx’s Medical Device for Emphysema

REDWOOD CITY, Calif.–(BUSINESS WIRE)– Pulmonx Corporation, a leader in interventional pulmonology, announced online publication today of results from the independent, randomized, controlled STELVIO trial in the New England Journal of Medicine. The trial demonstrated statistically and clinically significant outcomes in lung function, exercise capacity and quality of life in severe emphysema patients identified with the Chartis® System, Pulmonx’s proprietary assessment system, and treated with the Zephyr® Endobronchial Valve (EBV), when compared to those receiving standard medical management.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151209006607/en/

Zephyr® Endobronchial Valve (Photo: Business Wire) Zephyr® Endobronchial Valve (Photo: Business Wire)

The STELVIO trial is the first randomized, controlled trial of Zephyr EBV therapy using the Chartis System to identify patients most likely to benefit. It is also the first prospective trial to demonstrate that Zephyr EBV therapy can benefit a broad range of advanced stage emphysema patients, including those with heterogeneous disease, where emphysema is isolated to specific areas of the lungs, and homogeneous disease, where emphysema is distributed evenly throughout the lungs. The trial was performed independently of Pulmonx.

In the STELVIO trial, 68 patients were confirmed with the Chartis System to be likely responders to Zephyr EBV therapy, and randomized to either EBV therapy or medical management. In patients who received EBV therapy, tiny one-way valves were placed in the lungs to block airflow to diseased regions with the goal of improving breathing.

At six months, compared to the medical management group, the EBV group had statistically and clinically greater improvements in pulmonary function (FEV 1 change % predicted, EBV vs Control: 20.9% vs 3.1%; p=0.001), exercise capacity (6 Minute Walk Test, EBV vs Control: +19.6% vs -3.6%; p=0.001) and quality of life (SGRQ score, EBV vs Control: -21.8 vs -7.6; p=0.001). Also, a significantly greater number of patients in the EBV group responded to treatment. At the end of six months, control patients that crossed over to receive EBV therapy gained benefits similar to the original EBV-treated group.

The STELVIO trial was led by Karin Klooster and Dirk-Jan Slebos of the Department of Pulmonary Diseases and the Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, The Netherlands. The trial was funded by a Dutch government grant from ZonMW and the University Medical Center Groningen, The Netherlands.

“When we select patients with the Chartis System, endobronchial valve treatment provides improved lung function, exercise capacity, and quality of life,” said Karin Klooster, lead author of the publication. “When we identify the right patients for treatment, the improvements can be life-changing,“ said Principal Investigator Dr. Dirk-Jan Slebos.

“The STELVIO study provides independent confirmation that a broad range of patients with advanced emphysema have a high likelihood of achieving clinically meaningful benefits from Zephyr EBV therapy when a systematic approach is followed and careful patient selection is performed using the Chartis System,” said Pulmonx Chief Executive Officer Glen French.

The Zephyr EBV is a minimally-invasive treatment for severe emphysema that has been proven in over a decade of clinical experience to significantly improve the lung function, exercise tolerance and quality of life for patients receiving treatment. The Chartis System is utilized prior to the procedure to identify likely responders. In the procedure, tiny, one-way valves are placed in the lungs to block airflow to diseased regions to achieve lung volume reduction. As a result, the remaining healthy regions may function more efficiently, enabling better breathing and an improved quality of life for patients who can then perform more activities of daily life. Zephyr EBVs have been implanted globally in more than 10,000 patients.

About Pulmonx

Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com. To view a video of the Zephyr EBV procedure, click here.

The Zephyr ® EBV is an investigational device in the United States. Limited by U.S. law to investigational use.


Chronic Communications
Michelle McAdam
949-545-6654 or 310-902-1274

Check out our twitter: @NewsNovumpr